Noradrenergic Activity and Attention (NAA)

September 23, 2022 updated by: Mara Mather, University of Southern California

The Influence of Noradrenergic Activity on Attentional Control in Younger and Older Adults

Older adults demonstrate increased distractibility by task-irrelevant information which contributes to general cognitive impairment. However, it is yet unclear how changes in noradrenergic activity during aging influences attentional control. In the current study, tonic noradrenergic activity will be increased or decreased to investigate its behavioral and neural effects on attentional control.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Andy Kim, PhD
  • Phone Number: 213-740-5156
  • Email: andyk@usc.edu

Study Locations

    • California
      • Los Angeles, California, United States, 90089
        • Recruiting
        • USC Leonard Davis School of Gerontology
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Young adults will be recruited from the student population at the University of Southern California. Older adults will be recruited from a volunteer registry.

Description

Inclusion Criteria:

  • Fluent in English
  • Aged between 18-35 or 50-80
  • Have normal or corrected-to-normal vision and hearing, and normal color vision
  • Have a mobile phone and email address

Exclusion Criteria:

  • Non-English speakers
  • Currently practicing any relaxation, meditation, or breathing technique for more than an hour per week
  • Have participated in studies measuring attentional capture in the past year
  • Experiencing symptoms of dementia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Young Adults
Young Adults aged 18-35
Older Adults
Older Adults aged 50-80

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Initial eye-movements toward target and distractor shapes measured by an eye-tracker
Time Frame: Calculated once at the end of the 1 day experiment
The oculomotor suppression effect is a lower likelihood that salient display items will be the target of the initial eye movement in a visual search task compared to nonsalient display items. Using an eye-tracker, initial fixations toward the target, salient distractor, and nonsalient distractors will be compared as a measure of attentional control.
Calculated once at the end of the 1 day experiment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2021

Primary Completion (Anticipated)

November 1, 2023

Study Completion (Anticipated)

November 1, 2023

Study Registration Dates

First Submitted

October 13, 2021

First Submitted That Met QC Criteria

November 3, 2021

First Posted (Actual)

November 15, 2021

Study Record Updates

Last Update Posted (Actual)

September 27, 2022

Last Update Submitted That Met QC Criteria

September 23, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • UP-21-00711

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

At the conclusion of the study, data in de-identified form will be shared using the Open Science Framework and/or OpenNeuro Databases which are free and open platforms for sharing and archiving scientific data.

IPD Sharing Time Frame

Data will be made available at the end of the experiment, indefinitely.

IPD Sharing Access Criteria

Data will be uploaded to scientific data archiving platforms.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aging

3
Subscribe